The Financial Value of an Academic Neurologist

Academic neurology faces a persistent and consequential paradox, which is neurologists generate substantial value for their institutions through downstream clinical care and its associated revenue, research enterprise, and educational missions, yet many departments operate at or near financial break‐even and compensation models remain narrowly anchored to work revenue. This fundamental disconnect has been documented in recent analyses of national compensation data and institutional revenue generation. ¹ This situation stems from a fundamental failure of the relative value unit (RVU) system to capture the true financial impact of neurological practice.

The webinar confronts that paradox directly, integrating national compensation and productivity data with the lived experience of academic neurology leadership. In the webinar, Dr Adam de Havenon, an Associate Professor at Yale University, and Dr Joseph R. Berger, Professor Emeritus of University of Pennsylvania, examine the structural financial pressures facing academic neurology departments, including increasing clinical demand, institutional expectations, and the widespread perception of neurology as a low‐margin specialty. Speakers discuss contemporary national data on neurologist compensation and productivity, highlighting trends over the past decade. Finally, the discussion moves beyond revenue to present a more comprehensive framework for understanding a neurologist's value, encompassing downstream revenue from admissions, imaging, procedures, and therapeutics, as well as contributions from research funding and teaching.

Financial Crisis and Compensation Trends

The financial challenges for academic neurology are severe and pervasive. The majority of academic neurology departments operate at or below break‐even, with 83% experiencing moderate to severe financial pressure. ² Survey data from 2019 found only 31% of departments reported profit, while 41% operated at a loss averaging approximately $500,000 annually. ³ Dr de Havenon discussed that a national compensation analysis tracking 2,280 neurologists across 920 organizations from 2013 to 2023 revealed stagnant growth, for instance, inflation‐adjusted median neurologist compensation increased only 1.6%, rising from $313,315 to $318,284. ¹ This minimal growth contrasts sharply with other specialties. Neurosurgery compensation grew 5.0% over the same period ($790,336–$829,527), while even the lowest‐compensated specialty, pediatrics, grew 4.9% ($258,073–$270,666). The gap reflects the inadequacy of conventional compensation metrics. Neurology departmental financial struggles persist despite individual neurologists generating extraordinary institutional revenue, indicating systemic undervaluation rather than organizational inefficiency.

RVU Inadequacy with National Evidence

Dr Berger highlighted that RVU, created by the Centers for Medicare and Medicaid Services in 1992, have become the dominant compensation metric in academic medicine despite fundamentally misrepresenting neurological work. The RVU framework allocates 52% to physician work, 44% to practice expenses, and 4% to liability. This structure was designed for procedural specialties and fundamentally misaligns with cognitive and diagnostic practice. National data reveals critical disparities. Academic medical center neurologists generated a median of 2,969 work RVUs (wRVUs) annually, substantially lower than hospital‐based (4,863), neurology‐group (5,469), or multispecialty group (5,600) settings. ⁵ Academic neurologists were also among the lowest‐compensated, with median compensation of $277,288, well below hospital‐based ($362,500), multispecialty ($350,000), or neurology‐group ($315,489) settings. ⁴ , ⁵ Yet neurologists receive only $65 per wRVU in current compensation, less than neurosurgery ($90), orthopedic surgery ($76), or interventional cardiology ($68). ¹ More critically, the median neurologist receives approximately 75% of total compensation from evaluation and management codes, with over 20% dependent entirely on E/M services. ⁶ For specialists managing complex diagnostic workups, insurance authorizations, medication management, and patient education, this RVU‐dependent system generates minimal compensation despite creating substantial institutional value. The framework fails to capture the cognitive complexity and longitudinal care burden inherent to neurological practice.

Downstream Revenue Analysis

Downstream revenue encompasses all hospital and health system income generated from patient referrals for diagnostic studies, infusion therapies, specialty pharmacy services, and related care. This concept fundamentally reframes how academic health systems should assess physician financial value. Institutional research demonstrates extraordinary disparities between compensation and revenue generation. A 2012 study of academic neurologists found they generated $1,915,149 annually in combined technical and professional revenue, nearly three times the $691,406 reported for community neurologists. ⁷ By 2019, the average net annual revenue generated by a neurologist on behalf of their affiliated hospital had increased to $2.05 million. ⁸ For multiple sclerosis (MS) specialists, institutional analysis demonstrates individual neurologists generating approximately $8 million in downstream revenue annually through diagnostic studies, disease‐modifying therapy prescriptions, infusions, and specialty pharmacy services. Dr Berger noted that the revenue‐to‐compensation ratio for MS specialists who practice in an optimal environment can reach 44.4:1, far exceeding neurosurgeons (2.52:1), orthopedic surgeons (5.17:1), or cardiologists (4.24:1). ⁷ This extraordinary disparity reveals systematic failure of RVU‐based compensation to recognize cognitive, diagnostic, and procedural contributions generating substantial institutional revenue.

Sources of Revenue Breakdown (MS as a Case Study)

New patient evaluation generates substantial revenue through diagnostic imaging and specialized testing. Even conservative estimates for the profits from brain and spine magnetic resonance imaging and other diagnostic studies (eg, evoked potential batteries, optical coherence tomography; lumbar punctures; and comprehensive laboratory panels) reveal very considerable revenue streams for the institution. ⁷ Disease‐modifying therapy prescriptions routed through institutional specialty pharmacies operating under the Medicare 340B program are an enormous potential contributor to institutional revenue. ⁷ Dr Berger highlighted that the downstream revenue generated by a neurologist seeing 325 new MS patients annually and 700 follow‐up MS patients semiannually can easily reach millions of dollars from imaging and other diagnostic studies and the profits generated from an associated specialty pharmacy and infusion service. Additionally, the MS specialist and other neurological subspecialists are often the patient's initial entrée to the academic medical center and this often leads to referrals for other medical services at the institution with their associated revenue streams. These revenues are credited to entities other than the neurologist and their associated department of neurology resulting in institutional misalignments. The department remains under resourced and the MS neurologist's compensation reflects only RVU‐based E/M coding.

Regional and Subspecialty Trends

Geographic and subspecialty compensation analysis from 2013 to 2023 reveals concerning patterns. Regional compensation gaps have narrowed by over 50%, with the Northeast remaining the lowest‐compensated region while the West demonstrated the most rapid growth, suggesting geographic convergence occurring through inadequacy rather than improvement. ¹ Subspecialty trends are particularly troubling, as vascular neurology and neurohospitalists showed sustained compensation growth while epilepsy, neuromuscular disease, MS, and neurocritical care experienced compensation declines. ¹ Medical group neurologists earned 12% more than hospital‐employed neurologists in 2015, yet this gap narrowed to less than 1% by 2022, occurring through medical group compensation decline rather than hospital‐based improvement. ¹ Notably, downstream revenue generation does not appear directly linked to compensation models. Complex subspecialties generating the most downstream revenue through sophisticated diagnostics, infusions, and specialty pharmaceuticals experience the steepest compensation declines, revealing structural compensation failure.

Systemic Misalignment and Conclusions

The persistent gap between downstream revenue generation and neurologist compensation represents fundamental systemic misalignment. National compensation stagnation at 1.6% growth over a decade while neurosurgery grew 5.0% confirms the problem is structural and systemic, not individual or departmental. Compensation convergence between medical group and hospital‐based settings occurred through both receiving inadequate compensation rather than proper valuation. Subspecialties generating the most institutional revenue experience the most compensation decline, directly contradicting rational institutional incentive alignment. ¹ Neurologists generate more downstream revenue than non‐neurologists for the same diagnoses. ⁹ The problem is not individual negotiation failure or departmental policy variation, but rather systemic RVU‐based frameworks failing to capture cognitive complexity, diagnostic intensity, insurance navigation burden, and patient education time characterizing neurological practice. Healthcare administration growth exceeding physician growth by 3,200% between 1975 and 2010 suggests institutions have invested heavily in management while systematically undervaluing clinical contribution. ¹⁰ , ¹¹ , ¹² , ¹³

Call for Systemic Reform

Addressing compensation disparities requires fundamental systemic reform rather than incremental adjustment. ¹ Current RVU metrics fundamentally cannot capture the value of cognitive, diagnostic, and longitudinal clinical work. Academic health systems must recognize that neurologists generate revenue through multiple channels, such as, initial complex diagnostic workups, ongoing specialist consultations, pharmaceutical prescriptions routed through institutional specialty pharmacies, and sophisticated infusion services. These revenue sources represent institutional money flowing directly to health systems, but are inadequately reflected in physician compensation. For academic neurologists, understanding these financial dynamics is essential for career planning, negotiation, and departmental advocacy. For institutional leadership, ignoring the demonstrated financial value of neurology departments risks losing expertise in increasingly important clinical domains as neurologic disease burden accelerates with aging populations.

True systemic reform requires fundamentally reconsidering how academic health systems account for and compensate cognitive, diagnostic, and longitudinal clinical work rather than perpetuating procedurally oriented RVU frameworks that systematically undervalue neurology. The future of academic neurology depends on abandoning RVU models that reward procedures while discounting the expertise that defines neurological care.

Suggested Supplemental Material

URL for podcast episode: https://vimeo.com/1191201484?fl=pl&fe=cm.

Potential Conflicts of Interest

Nothing to report.